Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Novel and Potent Inhibitor of E-Selectin, GMI-1687, Attenuates Thrombus Formation and Augments Chemotherapeutic Intervention of AML in Preclinical Models Following Subcutaneous Administration

John Peterson, PhD, Myung-Gi Baek, PhD, Silvia Locatelli-Hoops, PhD, Ji-Won Lee, PhD, Lingquan Deng, PhD, David A Stewart, Theodore AG Smith, PhD, Daniel Durant Myers, DVM, MPH, William E Fogler, PhD, John L Magnani, PhD

Blood (2018) 132 (Supplement 1): 4678.

https://doi.org/10.1182/blood-2018-99-116779

Published: 2018

Journal Articles

A Novel Glycomimetic Compound (GMI-1757) with Dual Functional Antagonism to E-Selectin and Galectin-3 Demonstrates Inhibition of Thrombus Formation in an Inferior Vena Cava Model

John Peterson, PhD, Yusuf Vohra, PhD, Daniel Durant Myers, DVM, MPH, Silvia Locatelli-Hoops, PhD, Ji-Won Lee, PhD, Lingquan Deng, PhD, Theodore AG Smith, PhD, William E Fogler, PhD, John L Magnani, PhD

Blood (2018) 132 (Supplement 1): 2211.

https://doi.org/10.1182/blood-2018-99-118122

Published: 2018

Journal Articles

E-Selectin Antagonist GMI-1271 Shows a Favorable Safety, PK and Bleeding Profile in Phase I Studies of Healthy Volunteers

Dana E. Angelini, MD, Sumana Devata, MD, Angela E. Hawley, Susan A. Blackburn, RN, MBA, Satwinder Grewal, Martina V Hemmer, MA, Henry Flanner, MS, William Kramer, PhD, William E Parker, Yu-Ling Li, MS, MD, Daniel Durant Myers, DVM, MPH, James B. Froehlich, MD MPH, John L Magnani, PhD, Helen M. Thackray, MD, Thomas W. Wakefield, MD, Suman L. Sood, MD MSCE

Blood (2016) 128 (22): 3826.

https://doi.org/10.1182/blood.V128.22.3826.3826

Published: 2016

Journal Articles

First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile

Sumana Devata, MD, Suman L. Sood, MD, Martina V Hemmer, MA, Henry Flanner, MS, William Kramer, PhD, Christine Nietubicz, Angela Hawley, Dana E Angelini, MD, Daniel Durant Myers, DVM, MPH, Susan Blackburn, James Froehlich, MD, Thomas W. Wakefield, MD, John L. Magnani, PhD, Helen M. Thackray, MD

Blood (2015) 126 (23): 1004.

https://doi.org/10.1182/blood.V126.23.1004.1004

Published: 2015

Journal Articles

Soluble P-Selectin and Age Adjusted D-Dimer As Predictive Biomarkers of Venous Thrombosis

Dana E Angelini, MD, Cathy Stabler, R.N., Angela E. Hawley, Kenneth E. Guire, M.S., Daniel Durant Myers, DVM,MPH, Susan Blackburn, R.N., Thomas W. Wakefield, MD, Suman L. Sood, MD

Blood (2014) 124 (21): 2863.

https://doi.org/10.1182/blood.V124.21.2863.2863

Published: 2014

Journal Articles

E-Selectin Inhibitor GMI-1271 Works in Combination with Low-Molecular Weight Heparin to Decrease Venous Thrombosis and Bleeding Risk in a Mouse Model

Daniel Durant Myers, DVM,MPH, Shirely K. Wrobleski, BS, Krus Kelsey, Diana Farris, Diaz A. Jose, MD, Henke K. Peter, MD, Suman L. Sood, MD, Thomas W. Wakefield, MD, John L. Magnani, PhD

Blood (2014) 124 (21): 593.

https://doi.org/10.1182/blood.V124.21.593.593

Published: 2014

NARROW

A Novel and Potent Inhibitor of E-Selectin, GMI-1687, Attenuates Thrombus Formation and Augments Chemotherapeutic Intervention of AML in Preclinical Models Following Subcutaneous Administration

A Novel Glycomimetic Compound (GMI-1757) with Dual Functional Antagonism to E-Selectin and Galectin-3 Demonstrates Inhibition of Thrombus Formation in an Inferior Vena Cava Model

E-Selectin Antagonist GMI-1271 Shows a Favorable Safety, PK and Bleeding Profile in Phase I Studies of Healthy Volunteers

First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile

Soluble P-Selectin and Age Adjusted D-Dimer As Predictive Biomarkers of Venous Thrombosis

E-Selectin Inhibitor GMI-1271 Works in Combination with Low-Molecular Weight Heparin to Decrease Venous Thrombosis and Bleeding Risk in a Mouse Model

Email alerts

ASH Publications

American Society of Hematology

A Novel and Potent Inhibitor of E-Selectin, GMI-1687, Attenuates Thrombus Formation and Augments Chemotherapeutic Intervention of AML in Preclinical Models Following Subcutaneous Administration

A Novel Glycomimetic Compound (GMI-1757) with Dual Functional Antagonism to E-Selectin and Galectin-3 Demonstrates Inhibition of Thrombus Formation in an Inferior Vena Cava Model

E-Selectin Antagonist GMI-1271 Shows a Favorable Safety, PK and Bleeding Profile in Phase I Studies of Healthy Volunteers

First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile

Soluble P-Selectin and Age Adjusted D-Dimer As Predictive Biomarkers of Venous Thrombosis

E-Selectin Inhibitor GMI-1271 Works in Combination with Low-Molecular Weight Heparin to Decrease Venous Thrombosis and Bleeding Risk in a Mouse Model

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only